Clinical Trials Logo

Headache Disorders, Secondary clinical trials

View clinical trials related to Headache Disorders, Secondary.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05608642 Active, not recruiting - Clinical trials for Medication Overuse Headache

Intravenous Treatments Used in Medication Overuse Headache Bridge Treatment

Start date: October 22, 2022
Phase: N/A
Study type: Interventional

Medication overuse headache is the chronicity of headaches, which occurs more than 15 days a month, as a result of frequent use of painkillers, opioids or migraine attack drugs (ergotamine, triptan) in individuals with pre-existing primary headache disease. In the treatment of this headache, two ways can be followed as slow drug discontinuation or sudden drug discontinuation. The most commonly used method is the sudden discontinuation of the overused analgesic agent, the initiation of prophylactic treatment, and then the application of bridge therapy for 6-10 days. Intravenous hydration, steroids, antiemetics, neuroleptic drugs and local anesthetic drugs such as lidocaine can be used in bridge treatment.

NCT ID: NCT02993289 Active, not recruiting - Clinical trials for Medication Overuse Headache

Is Detoxification Needed in Medication-overuse Headache?

DEFINE3
Start date: October 24, 2016
Phase: N/A
Study type: Interventional

Medication-overuse headache (MOH) is a disabling condition, yet treatable. According to European guidelines and based on evidence, multidisciplinary detoxification is the first choice of treatment for MOH. However, consensus about the details in such detoxification programs is lacking. Contrary, other headache specialists believe more in treating chronic headache with medication overuse with single-therapy of prophylaxis and no withdrawal of acute medication, based on randomized controlled double-blinded placebo trial with prophylaxes. Only a single RCT has compared single-therapy with prophylaxis to detoxification. However there was no significant difference. AIM: 1. To compare three different treatment protocols in order to improve the therapy of MOH. 2. To test several baseline variables for being potential predictors for good treatment outcome. 3. To examine the role of epigenetics in MOH.